

Amendment to Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-5. (Canceled)

6. (Withdrawn) The composition of claim 1 in the form of a capsule.

7. (Withdrawn) The composition of claim 1 in the form of granulates.

8-12. (Canceled)

13. (Withdrawn) The composition of claim 10 in the form of a capsule.

14. (Withdrawn) The composition of claim 10 in the form of granulates.

15. (Canceled)

16. (Currently Amended) An orally administrable immediate release fenofibrate tablet, wherein the required daily dose is lower than 200 mg, and wherein the bioavailability is greater than that of Lipanthyl®200M (200 mg co-micronized fenofibrate[[]]).

17. (Canceled)

18. (Original) The tablet of claim 16, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

19. (Original) The tablet of claim 16, wherein the fenofibrate is present in an amount of 20 to 45% by weight.

20. (Original) The tablet of claim 16 which is once-daily.

21-24. (Canceled)

25. (Withdrawn) An orally administrable fenofibrate capsule with an enhanced bioavailability, whereby the required daily dose is lower than 200 mg.

26. (Withdrawn) The capsule of claim 25, wherein the capsule has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia,

in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.

27. (Withdrawn) The capsule of claim 25, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

28. (Withdrawn) The capsule of claim 25, wherein the fenofibrate is present in an amount of 20 to 45% by weight.

29. (Withdrawn) The capsule of claim 25 which is once-daily.

30. (Withdrawn) An orally administrable fenofibrate capsule with an enhanced bioavailability, whereby the required daily dose is lower than 200 mg, and wherein the capsule has a dissolution of at least 10% in 5 minutes, 20% in 10 minutes, 50% in 20 minutes and 75% in 30 minutes, as measured using the rotating blade method at 75 rpm according to the European Pharmacopoeia, in a dissolution medium constituted by water with 2% by weight polysorbate 80 or 0.025 M sodium lauryl sulfate.

31. (Withdrawn) The capsule of claim 30, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

32. (Withdrawn) The capsule of claim 30, wherein the fenofibrate is present in an amount of 20 to 45% by weight.

33. (Withdrawn) The capsule of claim 30 which is once-daily.

34-35. (Canceled)

36. (Original) The tablet according to claim 16, wherein the fenofibrate is in a non-reagglomerated form.

37. (Canceled)

38. (Withdrawn) The capsule according to claim 25, wherein the fenofibrate is in a non-reagglomerated form.

39. (Withdrawn) The capsule according to claim 30, wherein the fenofibrate is in a non-reagglomerated form.

40. (Canceled)

41. (Previously presented) The tablet according to claim 16, wherein the bioavailability is assessed by AUC, C_{max} or both.

42. (Currently amended) An orally administrable immediate release fenofibrate tablet, wherein the required daily dose is lower than 200 mg, and wherein the bioavailability is greater than that of Lipanthyl®200M (200 mg co-micronized fenofibrate[[]]), the bioavailability being assessed by AUC, C_{max} or both.

43. (Previously presented) The tablet of claim 42 which is once-daily.

44. (Previously presented) The tablet of claim 42, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

45. (Previously presented) The tablet of claim 42, wherein the fenofibrate is present in an amount of 20 to 45% by weight.

46. (Currently amended) An orally administrable once-daily immediate release fenofibrate tablet, wherein the required daily dose is lower than 200 mg, and wherein the bioavailability is greater than that of Lipanthyl®200M (200 mg co-micronized fenofibrate[[]]), the bioavailability being assessed by AUC and C_{max}.

47. (Previously presented) The tablet of claim 46, wherein the fenofibrate is present in an amount of 5 to 50% by weight.

48. (Previously presented) The tablet of claim 46, wherein the fenofibrate is present in an amount of 20 to 45% by weight.